Biofil Chemicals & Pharmaceuticals Ltd

Biofil Chemicals & Pharmaceuticals Ltd., a micro-cap pharmaceutical company with a market capitalisation of ₹57.00 crores, reported net profit of ₹0.21 crores in Q4 FY26 (Mar'26), marking a modest 5.00% increase year-on-year but a substantial 162.50% surge quarter-on-quarter. However, this apparent profitability improvement conceals deeper operational challenges, as the company's core business performance remains under significant pressure with volatile revenue patterns and contracting margins.

Biofil Chemicals & Pharmaceuticals Ltd has seen its investment rating upgraded from Strong Sell to Sell, reflecting a nuanced shift in its technical outlook and valuation metrics despite ongoing fundamental challenges. The upgrade, effective from 29 May 2026, is driven primarily by improved technical indicators and a more attractive valuation grade, while financial trends and quality scores remain subdued.

Biofil Chemicals & Pharmaceuticals Ltd has seen its investment rating upgraded from Sell to Strong Sell, driven primarily by shifts in technical indicators and valuation metrics. Despite persistent challenges in financial trends and quality fundamentals, the recent market performance and valuation adjustments have prompted this reassessment, signalling cautious investor sentiment amid mixed signals.

Biofil Chemicals & Pharmaceuticals Ltd has witnessed a notable shift in its valuation parameters, moving from a very attractive to an attractive rating, despite a challenging performance relative to the broader market. This change, driven primarily by adjustments in its price-to-earnings and price-to-book ratios, offers investors a fresh perspective on the stock’s price attractiveness within the Pharmaceuticals & Biotechnology sector.

At Rs 37.82, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Biofil Chemicals & Pharmaceuticals Ltd locked at its upper circuit of 19.99% on 26 May 2026, with buyers queuing and no sellers willing to part with shares.

Biofil Chemicals & Pharmaceuticals Ltd has seen its investment rating downgraded from Sell to Strong Sell as of 15 May 2026, reflecting deteriorating technical indicators and persistently weak financial fundamentals. The micro-cap pharmaceutical company’s stock has underperformed key benchmarks, prompting a reassessment across quality, valuation, financial trend, and technical parameters.

Biofil Chemicals & Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 07 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Biofil Chemicals & Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 07 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 22 April 2026, providing investors with the latest insights into its performance and outlook.

Biofil Chemicals & Pharmaceuticals Ltd has seen its investment rating upgraded from Strong Sell to Sell, reflecting a nuanced improvement in technical indicators and valuation metrics despite ongoing fundamental challenges. The micro-cap pharmaceutical company’s recent price surge and valuation appeal have prompted this reassessment, though financial trends and quality scores remain subdued.

At Rs 32.28, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Biofil Chemicals & Pharmaceuticals Ltd locked at its upper circuit of 9.98% on 7 Apr 2026, with buyers queuing and no sellers willing to part with shares.

Biofil Chemicals & Pharmaceuticals Ltd is rated 'Strong Sell' by MarketsMOJO. This rating was last updated on 16 February 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 02 April 2026, providing investors with the latest perspective on the company’s position.

Biofil Chemicals & Pharmaceuticals Ltd’s stock price declined to a fresh 52-week low of ₹26.36 on 30 March 2026, marking a significant milestone in its ongoing downward trajectory. The stock has underperformed both its sector and broader market indices, reflecting persistent challenges in its financial and market performance.

Despite a broadly positive market environment, Biofil Chemicals & Pharmaceuticals Ltd has succumbed to selling pressure, hitting a fresh 52-week low of Rs 27.99 on 27 Mar 2026. This decline comes amid a sharp underperformance relative to the Sensex, which itself is hovering near its own 52-week lows.